Catalent and Vaccinex today announced an agreement to develop an antibody-drug conjugate using Catalent’s proprietary SMARTag® and GPEx® technologies, and Vaccinex’s proprietary ActivMAb® technology.
Catalent today announced it has signed a multi-year agreement with Grid Therapeutics, LLC, for the development and manufacture of Grid’s lead therapeutic candidate for the treatment of solid tumors.
Catalent today announced it has completed the acquisition of Cook Pharmica LLC, an integrated provider of drug substance and drug product manufacturing and related services.
Catalent the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced it has reached an agreement to…
Catalent today announced that two of its biologics experts are to present at the upcoming INTERPHEX JAPAN exhibition and conference, to be held at Tokyo Big Sight from June 28 – 30, 2017.
Catalent today announced that it has signed an agreement with Therachon AG to support development of TA-46, a novel protein addressing achondroplasia, the most common form of short-limbed dwarfism.
